Prime moves up on Inc. Magazine’s Annual List of America’s Fastest-Growing Private Companies

For the 8th consecutive year, Prime appears on the Inc. 5000, ranking no. 1,073 with three-year revenue growth of 391 percent

August 14, 2019
Prime Therapeutics (Prime) improved its standing by more than 200 places – from 1,288 in 2018 to 1,073 in 2019 – in the 38th annual Inc. 5000, a ranking of the nation’s fastest-growing private companies by Inc. Magazine. This is the eighth straight year Prime has achieved this distinction. And since 2017 Prime has been part of a select group of companies on Inc. 5000’s “Honor Roll.” Fewer than a tenth of Inc. 5000 honorees to ever achieve this milestone.

The list includes the most successful American companies in the dynamic independent small businesses segment. Companies that made the list, on average, have grown six-fold since 2015.

“In a rapidly consolidating market, our superior partnership model is helping to drive consistent growth among our existing clients, new clients, and new markets,” said Rob Kelley, interim chief financial officer at Prime. “We should all be extremely proud of these results and understand that continued commitment to consumer-centric innovation and total drug management will continue to help us grow and climb in this ranking.”

The full list, including Prime’s company profile, is available and will publish in the September issue of Inc., a leading publication for entrepreneurs.

Related news

Stories

May 2, 2024

Prime discusses leading medically integrated dispensing model at Asembia 

Connecting specialty pharmacies and providers to unlock optimal care and value

Stories

April 30, 2024

RECAP: Academy of Managed Care Pharmacy (AMCP) Annual Meeting 2024

Stories, perspectives and news coverage of Prime Therapeutics/Magellan Rx from AMCP 2024

Stories

April 24, 2024

New study conducted by Prime Therapeutics researchers offers insights into ways to increase equity in health care

Research published in the Journal of Managed Care & Specialty Pharmacy uses population data to fill gaps in social determinants of health data, providing a more complete understanding of a patient’s global health circumstances